Doxorubicin HCl (Adriamycin generic) — HCPCS J9000

Doxorubicin formulation comparison — J9000 conventional vs Q2050 liposomal FDA verified May 2026

Same active molecule, very different drug. Different code, different label, different toxicity, different price (~26×).

Doxorubicin is delivered in two distinct FDA-approved IV products. Conventional doxorubicin HCl (the original Adriamycin and modern generics, J9000) is the free-drug solution. Pegylated liposomal doxorubicin (Doxil, Lipodox, Q2050) encapsulates the drug in long-circulating PEG-coated liposomes. They are not interchangeable, and substituting one J-code for the other on a claim is both a clinical error and a billing error.

Dosing matrix by regimen NCCN + FDA label May 2026

Conventional doxorubicin appears in many regimens at different doses. Verify the prescribed dose against the named regimen at PA submission.

Worked example — AC adjuvant breast, 1.7 m² patient, 60 mg/m²

Combo sequencing — R-CHOP and ABVD admin order

For R-CHOP: rituximab first (separate non-chemo admin code 96413 or 96365 per payer), then cyclophosphamide, then doxorubicin (IV push or short infusion), then vincristine, then oral prednisone days 1–5. Bill sequential chemo admin codes per CPT hierarchy: 96413 for initial / longest infusion and 96417 for each additional sequential substance; 96409 for the doxorubicin IV push if pushed rather than infused. For ABVD: doxorubicin first IV push, then bleomycin, vinblastine, dacarbazine on Days 1 and 15 of each 28-day cycle.

Dose modification for hepatic impairment

Doxorubicin is hepatically cleared. Dose-reduce by total bilirubin: bili 1.2–3.0 mg/dL → give 50%; bili 3.1–5.0 mg/dL → give 25%; bili >5.0 mg/dL → do not administer. Document pre-cycle LFTs in the chart. Payer audits frequently look for hepatic-impairment dose-adjustment documentation on lymphoma and breast-cancer claims for patients with elevated baseline bili.

NDC reference — multi-manufacturer landscape FDA NDC Directory verified May 2026

J9000 is a multi-source generic with many FDA-approved manufacturers. Representative NDCs below; verify the 11-digit NDC on the actual dispensed carton for each patient and submit on the claim. Any FDA-approved conventional (non-liposomal) doxorubicin HCl labeler NDC is acceptable under J9000.

Administration codes CPT verified May 2026

Conventional doxorubicin is administered either as an IV push (3–5 minutes through a free-flowing IV) or as a short IV infusion (10–30 minutes), per institutional protocol and patient venous access. CPT differs between the two routes.

Modifiers CMS verified May 2026

JZ / JW — one required on every single-dose vial claim

Effective July 1, 2023, CMS requires JZ on every single-dose container claim with no waste, and JW for the discarded portion when waste exists. BSA-based doxorubicin dosing with fixed vial sizes frequently produces partial-vial waste — bill JZ on the administered units and JW on the wasted units on a separate claim line. One of JZ or JW must appear on every J9000 claim.

Worked modifier example — R-CHOP, 1.7 m², 50 mg/m² = 85 mg

• Patient 1.7 m² on R-CHOP, doxorubicin 50 mg/m² → 85 mg dose
• Vials used: one 100 mg vial (e.g., 50 mg/25 mL twice, or one 50 + draw partial 50) — assume two 50 mg vials = 100 mg total drawn
• Administered: 85 mg = 9 units (rounded up from 8.5) → bill 9 units of J9000 with JZ
• Discarded: 15 mg = 2 units (rounded per MAC) → bill 2 units of J9000 with JW on a separate claim line

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation is performed on the same day as the infusion. Routine pre-cycle clinical assessment is bundled into the chemo admin code.

340B modifiers (JG, TB)

For 340B-acquired doxorubicin, follow your MAC's current 340B modifier policy. Generic doxorubicin is commonly 340B-eligible at qualifying entities; verify the modifier requirement at your local MAC and OPPS payment context.

ICD-10-CM by indication FY2026 verified May 2026

Site of care & place of service Verified May 2026

Most major commercial payers run aggressive site-of-care utilization management for IV oncology infusibles. UnitedHealthcare and Aetna steer toward physician office, ambulatory infusion suite, or oncology ASC and away from hospital outpatient (HOPD) after the first 1–3 cycles unless toxicity management or vesicant-extravasation risk requires HOPD-level support. Home infusion is generally not used for IV doxorubicin due to the vesicant risk and the need for trained admin + on-site extravasation kit.

Claim form field mapping Verified May 2026

Concrete claim example — AC adjuvant breast, 1.7 m²

• Dose: 60 mg/m² × 1.7 = 102 mg; vial used: one 150 mg / 75 mL single-dose vial (NDC 0143-9279-01)
• Line 1 (admin): J9000 × 11 units, modifier JZ, ICD-10 C50.911
• Line 2 (waste): J9000 × 5 units (48 mg / 10, rounded per MAC), modifier JW, same ICD-10
• Line 3 (admin CPT): 96409 (IV push) × 1
• Line 4 (combo drug): J9070 cyclophosphamide units + appropriate modifiers (same day)
• Line 5 (combo admin): 96413 for cyclophosphamide infusion (longest infusion = initial)

Payer policy snapshot Reviewed May 2026

Step therapy

Doxorubicin is itself a backbone agent (AC, R-CHOP, ABVD), so step therapy through doxorubicin is not a typical pattern. The relevant step-therapy questions are upstream (e.g., generic biosimilar rituximab for R-CHOP; preferred trastuzumab biosimilar for AC-TH regimens) — doxorubicin itself is single-source HCPCS J9000 across all generic manufacturers.

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Coverage

No NCD specific to doxorubicin. Coverage falls under MAC LCDs for cytotoxic chemotherapy and the on-label / NCCN-compendium framework. All MACs cover J9000 for FDA-approved on-label indications with appropriate ICD-10 documentation and LVEF baseline.

Patient assistance — foundation-based (no manufacturer hub) Verified May 2026

Conventional doxorubicin is a commodity generic with low ASP (~$0.27/mg) — manufacturers do not run dedicated patient hubs. Patient cost-share for the drug itself is typically modest; the cost concentration is in the combo agents (rituximab biosimilar, cyclophosphamide, paclitaxel) and the admin / supportive care. Patient assistance for doxorubicin defaults to disease-state foundations.

• CancerCare Co-Payment Assistance Foundation: 1-866-552-6729 · cancercare.org/copayfoundation — verify open funds for breast cancer, lymphoma (DLBCL / Hodgkin), AML, sarcoma, ovarian; income eligibility typically ≤500% FPL
• PAN Foundation: 1-866-316-PANF (7263) · panfoundation.org — disease-state funds (DLBCL, multiple myeloma, breast cancer, ovarian, soft-tissue sarcoma, others); income limits typically ≤500% FPL; status-monitoring required (funds open and close)
• HealthWell Foundation: 1-800-675-8416 · healthwellfoundation.org — cancer treatment support funds; eligibility verified per fund
• Leukemia & Lymphoma Society (LLS) Co-Pay Assistance Program: 1-877-557-2672 · lls.org/finances — specifically for blood cancers (lymphoma, leukemia, myeloma, MDS)
• Patient Advocate Foundation (PAF) Co-Pay Relief: 1-866-512-3861 · copays.org — chronic-disease + cancer copay assistance; verify open funds
• Manufacturer patient assistance: Pfizer Patient Assistance Foundation (Hospira / Pfizer-labeled doxorubicin), Hikma Patient Assistance, and other generic-manufacturer PAPs for uninsured / underinsured patients — verify by current dispensed label
• 340B: generic doxorubicin is commonly 340B-eligible at qualifying entities — significantly reduces acquisition cost (apply JG or TB modifier per MAC policy)

Cardiotoxicity & cumulative dose tracking FDA boxed warning

Required cardiac monitoring

• Baseline LVEF (echo or MUGA) before initiating doxorubicin — payer-mandated PA element on UHC, Aetna, BCBS oncology policies.
• Serial LVEF per institutional anthracycline cardiotoxicity protocol — typically every 100–150 mg/m² cumulative, before each cycle approaching 450 mg/m², and at end-of-treatment.
• Cardio-oncology consult for baseline LVEF <55%, prior anthracycline exposure, prior chest RT, or other cardiac risk factors.
• Stop or hold therapy if LVEF drops >10 percentage points from baseline or below institutional threshold (commonly <50%).

Cumulative dose tracking workflow

• At Cycle 1: capture prior anthracycline exposure (drug, total dose) from prior treatment records.
• Convert prior exposures to doxorubicin equivalents (e.g., daunorubicin 1 mg = doxorubicin 0.5 mg equivalent; idarubicin 1 mg = doxorubicin 5 mg; mitoxantrone 1 mg = doxorubicin 4 mg; Doxil mg-for-mg). Use institutional protocol.
• Add cumulative doxorubicin mg/m² after each cycle; record running total in the chart.
• Trigger cardio-oncology consult and consider holding therapy as cumulative exposure approaches 450 mg/m².
• At 450–550 mg/m²: do not exceed without explicit informed-consent and documented benefit/risk discussion.

Vesicant extravasation protocol — dexrazoxane (Totect / J1190) FDA boxed warning

Immediate management at extravasation

• STOP the infusion immediately. Do not flush.
• Disconnect the IV tubing from the catheter but leave the catheter in place; aspirate any residual drug from the catheter and surrounding tissue using a small syringe.
• Remove the catheter only after attempted aspiration.
• Apply cold compresses 15–20 minutes 4×/day for the first 24–48 hours (do NOT use heat or warm compresses for anthracyclines — heat is appropriate for vinca alkaloids and oxaliplatin, but worsens anthracycline tissue damage).
• Elevate the affected limb.
• Notify the prescribing oncologist and the patient access / pharmacy team immediately for stat dexrazoxane (Totect / J1190) dispensing.

Dexrazoxane (Totect, J1190) — severe extravasation antidote

• FDA-approved antidote for severe anthracycline extravasation; mitigates tissue necrosis if administered within 6 hours of the extravasation event.
• Dosing schedule: 1,000 mg/m² IV over 1–2 hours within 6 hours of extravasation; 1,000 mg/m² IV at 24 hours; 500 mg/m² IV at 48 hours. Cap each daily dose at 2,000 mg.
• Administration: Infuse via a different limb/vein than the extravasation site, over 1–2 hours in 1,000 mL diluent (saline or D5W).
• Avoid dimethyl sulfoxide (DMSO): historical topical DMSO for anthracycline extravasation is contraindicated when dexrazoxane is given (no efficacy benefit, may reduce dexrazoxane effectiveness).

Billing the extravasation event

• Dexrazoxane: HCPCS J1190 (Injection, dexrazoxane HCl, per 500 mg) — calculate units by 500 mg basis (1,000 mg dose = 2 units, plus admin codes 96413/96415 for IV infusion over 1–2 hours).
• ICD-10: T80.81XA Extravasation of vesicant agent, initial encounter, plus T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter.
• Documentation: chart the extravasation event (time, estimated volume extravasated, vein/site, presenting symptoms), the interventions (aspiration, cold compress, dexrazoxane administration with times), and follow-up plan (tissue evaluation, plastics consult if needed).
• Emergency PA: commercial payers typically authorize Totect for documented anthracycline extravasation; for Medicare FFS, dexrazoxane for extravasation is covered under the on-label / FDA-approved indication.

Counseling on red urine / red secretions

Doxorubicin is a deep red anthracycline pigment. Counsel patients before the first dose that red-orange urine, tears, sweat, and saliva for 1–2 days post-infusion are normal, expected, and harmless — this is dye discoloration, not blood or hematuria. Not billing- relevant but a high-frequency triage-line call at first encounter; chair-side patient education materials should mention it explicitly.

Common denials & how to fix them

Frequently asked questions

Doxorubicin vs Doxil — which J-code do I bill?

Two different drugs, two different codes. Conventional doxorubicin HCl (Adriamycin generic, the free-drug solution) bills under J9000 — 10 mg = 1 unit, Q2 2026 ASP+6% ~$2.729/unit. Pegylated liposomal doxorubicin (Doxil, Lipodox) bills under Q2050 — also 10 mg = 1 unit but ~$71.861/unit, roughly 26× more expensive. They are not interchangeable. Match the J-code to the formulation actually administered. See the formulation comparison and the separate Doxil / Lipodox (Q2050) page.

What is the lifetime cumulative dose limit for doxorubicin?

Traditional ceiling is 450 mg/m² lifetime cumulative for patients without additional cardiac risk factors, extending to 550 mg/m² with strict cardiac monitoring (institutional protocols vary). The cap is a lifetime total across all anthracyclines — count prior Doxil (Q2050), daunorubicin, idarubicin, and mitoxantrone exposure converted to doxorubicin equivalents. Pediatric cap is typically lower (~300 mg/m²). See cardiotoxicity & cumulative dose tracking.

Is baseline cardiac monitoring required?

Yes. Baseline LVEF (echo or MUGA) is required before initiating doxorubicin and is a payer-mandated PA element on most UHC, Aetna, BCBS oncology medical-drug policies. Re-assess per institutional anthracycline protocol — typically every 100–150 mg/m² cumulative dose, before cycles approaching the cap, and at end-of-treatment. Cardio-onc consult for baseline LVEF <55%, prior anthracycline exposure, prior chest RT, or other cardiac risk factors.

How do I bill the vesicant extravasation management?

Severe extravasation calls for dexrazoxane (Totect, HCPCS J1190, 500 mg = 1 unit) within 6 hours: 1,000 mg/m² IV first dose, 1,000 mg/m² at 24 hours, 500 mg/m² at 48 hours (cap each daily dose at 2,000 mg). Bill J1190 units + admin codes 96413/96415. ICD-10: T80.81XA Extravasation of vesicant agent, initial encounter, plus T45.1X5A Adverse effect of antineoplastic drugs. Notify the patient access team immediately for stat Totect dispensing.

AC vs R-CHOP vs ABVD — how does doxorubicin dosing differ?

AC (breast adjuvant): 60 mg/m² IV Day 1, q21 days × 4 cycles. R-CHOP (DLBCL): 50 mg/m² IV Day 1, q21 days × 6–8 cycles. ABVD (Hodgkin): 25 mg/m² IV Days 1 + 15, q28 days. Single-agent palliative: 60–75 mg/m² q21 days. Verify the prescribed dose against the named regimen at PA submission. See the dosing matrix.

Pediatric ALL / Wilms tumor — same J-code?

Yes — J9000 applies regardless of patient age. Pediatric ALL induction/consolidation: 25–30 mg/m²/dose per COG protocol. Wilms tumor (DD-4A / EE-4A / M / I regimens): 45 mg/m² per cycle. ICD-10s C91.0x (ALL) and C64.x (Wilms). Pediatric cumulative cap is typically 300 mg/m² (lower for concurrent chest RT or infants); pediatric institutions use serial echocardiography per COG protocol. Pediatric payer PA criteria typically demand this documentation.

What is the Medicare reimbursement for J9000?

For Q2 2026, the Medicare Part B payment limit for J9000 is $2.729 per 10 mg unit (ASP + 6%). AC dose at 1.7 m² (102 mg = 11 units) ≈ $30.02 per cycle. R-CHOP dose at 1.7 m² (85 mg = 9 units) ≈ $24.56 per cycle. Doxil/Q2050 by comparison is $71.861 per 10 mg unit — conventional doxorubicin is approximately 26× cheaper per mg. Sequestration (~2%) reduces actual paid amount.

Red urine, red sweat, red tears — should I worry?

No — this is normal, expected, and harmless. Doxorubicin is a deep red anthracycline pigment and patients commonly report red-orange urine, tears, sweat, and saliva for 1–2 days post-infusion. It is dye discoloration, not blood or hematuria. Counsel patients before the first dose so the appearance does not cause distress. Not billing-relevant but a frequent triage-line call.

Source documents

1. DailyMed — Doxorubicin Hydrochloride Injection Prescribing Information (multi-labeler)
   FDA-approved label, current revisions (Hikma, Hospira/Pfizer, Teva, Accord, Fresenius Kabi, Sun Pharma)
2. FDA Drugs@FDA — Adriamycin original NDA 050467 (Pharmacia / Pfizer originator)
3. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
4. SEER CanMED — HCPCS J9000 reference
5. NCCN Clinical Practice Guidelines
   Breast Cancer, B-Cell Lymphomas (DLBCL), Hodgkin Lymphoma, AML, Soft-Tissue Sarcoma, Pediatric Cancers (Wilms, ALL)
6. DailyMed — Totect (dexrazoxane) Prescribing Information
   Anthracycline extravasation antidote, J1190
7. UnitedHealthcare — Oncology Medication Clinical Coverage Policy
8. Aetna — Clinical Policy Bulletins (oncology medical drugs)
9. FDA National Drug Code Directory
10. CancerCare Co-Payment Assistance Foundation
    1-866-552-6729
11. PAN Foundation — disease-state copay assistance
12. HealthWell Foundation — cancer treatment support

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 21, 2026 — Initial publication. ASP data: Q2 2026. FDA label: current multi-labeler (Hikma, Hospira/Pfizer, Teva, Accord, Fresenius Kabi). Formulation comparison vs Doxil/Lipodox (Q2050) called out prominently. Cumulative 450–550 mg/m² cap, baseline LVEF, vesicant extravasation (J1190 / Totect) protocol included.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication list is verified against the current FDA label revision and NCCN guidelines. We do not paraphrase from billing-software vendor blogs.